SAB4200779
Anti-NRAS (C-terminal) antibody produced in rabbit
IgG fraction of antiserum
Synonyme(s) :
GTPase NRas, Transforming protein N-Ras
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
rabbit
Niveau de qualité
Forme d'anticorps
IgG fraction of antiserum
Type de produit anticorps
primary antibodies
Clone
polyclonal
Forme
buffered aqueous solution
Poids mol.
predicted mol wt ~21 kDa
Espèces réactives
human
Validation améliorée
recombinant expression
Learn more about Antibody Enhanced Validation
Technique(s)
immunoblotting: 1:2,000-1:4,000 using human HEK-293T cells over-expressing NRAS protein
Numéro d'accès UniProt
Conditions d'expédition
dry ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... NRAS(4893)
Description générale
Transforming protein N-Ras (NRAS), also known as GTPase NRas or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family and are low molecular-weight GTPases. NRAS is mapped to human chromosome location 1p13.2 and shows ubiquitous expression. Ras proteins have highly homologous primary amino acid sequence and differ in their C-terminal region termed as hypervariable region (HVR).
Spécificité
Anti-NRAS (C-terminal) antibody specifically recognizes human NRAS and does not cross-react with HRAS or KRAS.
Immunogène
Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH
Application
Anti-NRAS (C-terminal) antibody produced in rabbit has been used in immunoblotting.
Actions biochimiques/physiologiques
Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS) was the first melanoma oncogene to be identified. Oncogenic NRAS mutations are single base substitutions (most commonly affecting residues G12, G13, or Q61) that lead to the stabilization of GTP binding and constitutive activation of RAS and downstream signaling cascades. Abnormal NRAS activity stimulates several signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), serine/threonine-protein kinase (RAFs) (ARAF, BRAF, and CRAF), phosphatidylinositol 3-kinase (PI3K) and the RAS-like protein (RAL) guanine nucleotide exchange factors (GEFs) signaling pathways. This leads to uncontrolled cell proliferation, resistance to apoptosis and thus cancer therapy potential target. NRAS mutations are present in various cancers, including melanomas, acute myeloid leukemia, colon, thyroid and lung cancers. Mutations are also implicated in hematologic malignancies, including acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and chronic myelomonocytic leukemia.
Forme physique
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Stockage et stabilité
For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Clause de non-responsabilité
Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma
Puig-Butille JA, et al.
Experimental Dermatology, 22(2), 148-150 (2013)
Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique